PLA2G7 and cardiovascular disorder: Therefore, Lp-PLA2 is regarded as a risk factor for cardiovascular disease, and darapladib (SB-480848) was developed to specifically inhibit Lp-PLA2 to treat atherosclerosis, although darapladib recently failed in phase III clinical trials due to lack of efficacy41–43.